{"product_id":"rmd-bcg-matrix","title":"(RMD) ResMed Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ResMed Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAirSense 11 flagship CPAP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAirSense 11 is a Star for ResMed Inc.: it anchors the company’s biggest therapy area, with FY2025 revenue of about $5.1 billion across sleep and breathing care. Its connected features support recurring mask, tube, and filter replacement demand, while ResMed’s distribution reaches about 140 countries. That mix of scale, data connectivity, and repeat sales keeps AirSense 11 in a high-growth, high-share spot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAirView cloud monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAirView cloud monitoring sits at the center of ResMed’s remote therapy management, linking patients, clinicians, and devices in one workflow. ResMed’s FY2025 revenue was about US$5.1 billion, and this connected-care layer helps protect that base by making therapy follow-up easier and device switching less likely. In BCG terms, AirView acts like a growth engine in connected respiratory care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emyAir patient app\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003emyAir supports adherence, education, and troubleshooting, so it helps ResMed keep sleep apnea patients active after the device sale. ResMed reported FY2025 revenue of $5.1 billion, and this app-backed model helps support that scale by extending the connected care ecosystem. It also raises long-term retention by keeping users engaged with therapy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAirFit and AirTouch masks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAirFit and AirTouch sit in ResMed Inc.'s core mask franchise, where demand is sticky because cushions and masks wear out and are replaced on a regular cycle. In fiscal 2025, ResMed Inc. reported $5.1 billion in revenue, and masks\/supplies stay one of the most recurring parts of that base. That keeps the line in a high-share, high-growth BCG position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring replacement demand supports sales.\u003c\/li\u003e\n\u003cli\u003eMask systems are a core franchise.\u003c\/li\u003e\n\u003cli\u003eStrong share keeps growth durable.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMatrixCare care management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMatrixCare is a strong Star because it serves senior living, skilled nursing, and hospice, three care settings where demand keeps rising as the 65+ population grows and providers digitize post-acute workflows. Its subscription software model supports recurring revenue, and that matters because ResMed can scale share without tying growth to one-off hardware sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets high-need post-acute care.\u003c\/li\u003e\n\u003cli\u003eBenefits from aging demographics.\u003c\/li\u003e\n\u003cli\u003eRecurring subscriptions support expansion.\u003c\/li\u003e\n\u003cli\u003eDigitization lifts software adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed’s Connected Care Engines Power FY2025 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed Inc.’s Stars are its connected sleep and respiratory care engines: AirSense 11, AirView, myAir, and the AirFit\/AirTouch mask family. In FY2025, ResMed Inc. reported about US$5.1 billion in revenue, backed by sales in about 140 countries. Their growth comes from connected use, repeat supply replacement, and high patient retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirSense 11\u003c\/td\u003e\n\u003ctd\u003eCore growth device\u003c\/td\u003e\n\u003ctd\u003eDrives therapy demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirView\u003c\/td\u003e\n\u003ctd\u003eCloud workflow layer\u003c\/td\u003e\n\u003ctd\u003eLowers switching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emyAir\u003c\/td\u003e\n\u003ctd\u003eAdherence support\u003c\/td\u003e\n\u003ctd\u003eLifts retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirFit\/AirTouch\u003c\/td\u003e\n\u003ctd\u003eRecurring replacements\u003c\/td\u003e\n\u003ctd\u003eSticky mask franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eResMed’s BCG Matrix maps its sleep and respiratory units into Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePain-point reliever: ResMed Inc. BCG Matrix puts each unit in one clean quadrant for fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear, credible source trail for ResMed Inc. that supports faster due diligence and more defensible decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAirSense 10 installed base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAirSense 10 still anchors a huge installed base in sleep therapy, so replacement sales and accessories keep flowing with little new-customer spend. ResMed reported FY2025 revenue of $5.08 billion, and this mature platform helped support that cash generation. That is classic high-share cash cow behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrightree home care software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrightree is ResMed Inc.'s mature HME, pharmacy, infusion, orthotics, and prosthetics software platform, so it fits the Cash Cow box. ResMed reported FY2025 revenue of $5.15 billion and gross margin of 58.5%, showing strong cash generation from recurring software and services. The market is steadier than newer digital care products, with Brightree acting as a dependable, lower-growth profit engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstral ventilators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstral ventilators fit ResMed Inc.’s Cash Cows: they serve chronic respiratory and home ventilation patients, where demand is steady and replacement-driven. ResMed Inc. reported FY2025 revenue of $5.09 billion and net income of $1.39 billion, showing strong cash generation from mature lines like Astral. The platform is established, so it supports dependable margins rather than fast growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAirCurve bilevel devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAirCurve bilevel devices are a mature ResMed line with an established installed base, so they fit the Cash Cow role in the BCG matrix. ResMed’s FY2025 revenue was US$4.69 billion, and its Devices segment kept benefiting from repeat replacement demand rather than a new-market spike. The line serves a stable clinical need in bilevel therapy, which supports steady cash generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature, replacement-driven demand\u003c\/li\u003e\n\u003cli\u003eStrong installed base\u003c\/li\u003e\n\u003cli\u003eStable cash contributor\u003c\/li\u003e\n\u003cli\u003eFY2025 revenue: US$4.69 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReplacement masks and accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReplacement masks, headgear, and cushions are ResMed Inc.’s steady cash cow because patients replace them regularly, and they stay tied to the company’s installed device base. In FY2024, ResMed Inc. reported $4.69 billion in revenue, with recurring consumables helping support gross margin and cash flow even when device growth is slower. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eRecurring replacement demand\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLow growth, high stickiness\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLight promo spend, steady cash\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese sales are less cyclical than new device sales, so they keep revenue flowing with little extra marketing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed’s Cash Cows: Installed Base Turning Into Steady Profit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed Inc.’s cash cows are its mature, replacement-led lines: AirSense 10, AirCurve, Astral, Brightree, and masks. In FY2025, ResMed Inc. posted US$5.08 billion revenue, 58.5% gross margin, and US$1.39 billion net income, showing how these low-growth businesses keep cash flowing from a large installed base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices and consumables\u003c\/td\u003e\n\u003ctd\u003eInstalled base, repeat sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrightree\u003c\/td\u003e\n\u003ctd\u003eRecurring software revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eResMed Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe ResMed Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No watermarks, no demo content—just the full, ready-to-use report. Download it instantly and use it for strategy, analysis, or presentations right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEALTHCAREfirst platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEALTHCAREfirst is a niche software asset inside ResMed Inc., serving home health and hospice agencies with EHR and billing tools. In a crowded post-acute software market, its share is likely modest, and slower category growth makes it fit the Dogs box in a BCG matrix. ResMed reported FY2025 revenue of about US$5.1 billion, but HEALTHCAREfirst does not appear to be a major growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy diagnostic equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy diagnostic equipment sits outside ResMed Inc.'s main connected-device growth engine; FY2025 revenue was about $5.1 billion, but the newer digital and cloud-linked lines drove the better mix. Demand is mostly replacement-led, so volume growth is slower than in connected therapy devices. That makes these products more exposed to price pressure and commoditization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder consumer sleep products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder consumer sleep products are a small, non-core part of ResMed’s FY2025 $5.15 billion revenue base, which grew 10% year over year. They face weaker brand pull than the company’s prescription PAP and mask franchises, so share stays low and growth is thin. That makes them fit the \"dog\" box in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder connectivity modules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder connectivity modules fit the Dogs bucket because they support legacy installs, but newer cloud-first workflows have taken the growth lead. In FY2025, ResMed kept scaling its connected ecosystem, yet these older units added little strategic lift and mainly protected service continuity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy hardware: operational, not growth-led\u003c\/li\u003e\n\u003cli\u003eCloud workflows now drive the value pool\u003c\/li\u003e\n\u003cli\u003eThin strategic value versus newer platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall regional accessory lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed Inc. posted FY2025 revenue of US$5.08 billion, so small regional accessory lines sit far below the global core franchise in scale. These lines can still absorb sales, logistics, and regulatory support without building meaningful share, which fits classic dog territory in a BCG Matrix. If growth stays weak and share stays thin, capital is better used on core masks and devices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow scale versus US$5.08B core\u003c\/li\u003e\n\u003cli\u003eSupport cost can outrun share gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed’s Dog Assets: Low Growth, Low Lift, Capital Drains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in ResMed Inc.'s BCG Matrix are small, slow-growth legacy lines like HEALTHCAREfirst, older diagnostic gear, and older connectivity modules. They sit far from the FY2025 revenue base of about US$5.08 billion to US$5.15 billion, so they add limited strategic lift and face price pressure. Capital is better used on core masks, PAP devices, and cloud-linked workflows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003eFY2025 view\u003c\/th\u003e\n\u003cth\u003eBCG signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEALTHCAREfirst\u003c\/td\u003e\n\u003ctd\u003eNiche, low share\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy diagnostics\u003c\/td\u003e\n\u003ctd\u003eReplacement-led demand\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlder connectivity modules\u003c\/td\u003e\n\u003ctd\u003eLow strategic lift\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePropeller solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePropeller solutions sits in a question mark bucket: it targets digital respiratory management for asthma and related chronic care, a large market, but ResMed does not lead it the way it does PAP and masks. The platform was built for connected inhaler and symptom tracking, but share gains are still unproven. That makes it a growth bet, not a cash engine, with adoption tied to payer and provider uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU-Sleep compliance tracking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU-Sleep is still a Question Mark: it targets home medical equipment compliance workflows, and that market is growing as obstructive sleep apnea affects about 1 billion adults worldwide. But it must beat entrenched workflow software and prove it can scale beyond a niche use case. \u003c\/p\u003e\n\u003cp\u003eThat means ResMed Inc. likely needs more investment in product, sales, and integration to turn U-Sleep into a leader. Without faster adoption and clear economics, it stays a low-share, high-upside bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDental devices fit ResMed Inc.’s Question Mark bucket: oral appliance therapy is tied to the fast-growing sleep-apnea market, but it is not a core share leader for the Company. ResMed reported FY2025 revenue of about $5.2 billion, yet it does not break out dental devices as a major standalone line, which signals limited current scale. If adoption rises in the oral-appliance segment, this could turn into a stronger growth option, but today it still lacks clear dominance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAI analytics add-ons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed Inc. AI analytics add-ons sit in the Question Marks quadrant: they can sharpen clinical insight, improve adherence, and cut service time, but their monetization is still early. In FY2025, ResMed Inc. posted about $5.1 billion in revenue, showing strong scale, yet these add-ons have not clearly turned into major profit drivers.\u003c\/p\u003e\n\u003cp\u003eThe market for AI in respiratory and sleep care is growing fast, but share and pricing power are still forming. That makes these tools promising, but not yet proven stars in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI lifts insight and efficiency.\u003c\/li\u003e\n\u003cli\u003eFY2025 revenue: about $5.1 billion.\u003c\/li\u003e\n\u003cli\u003eGrowth is real; monetization is not.\u003c\/li\u003e\n\u003cli\u003eStill a Question Mark, not a Star.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational SaaS expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed Inc.’s international SaaS push is a question mark: FY2025 revenue was about $5.1 billion, but SaaS growth outside North America still depends on local rules, payer ties, and channel execution. The upside is clear, yet share gains stay limited until scale and repeatable go-to-market reach land.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025 revenue: about $5.1 billion\u003c\/li\u003e\n\u003cli\u003eGrowth outside North America needs local fit\u003c\/li\u003e\n\u003cli\u003eScale must come before strong share gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed’s Question Marks: Early Growth Bets With Big Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed Inc.’s Question Marks are growth bets with low current share, including Propeller, U-Sleep, dental devices, AI add-ons, and international SaaS. FY2025 revenue was about $5.1 billion, but these units are still early in monetization and scale. They could move up only if adoption, payer fit, and integration improve fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePropeller\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eGrowth market, unproven share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU-Sleep\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eNeeds wider workflow adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191851852041,"sku":"rmd-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rmd-bcg-matrix.webp?v=1783678602","url":"https:\/\/dcfanalyst.com\/products\/rmd-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}